After examining vitamin D receptor (VDR) Cdx2 genotype and calcium intake in 533 African-American men with prostate cancer (PCa) and 250 control subjects, Gary G. Schwartz, PhD, and colleagues found that men in the highest quartile of calcium intake had a 2.2 times increased risk of localized and advanced PCa compared with men in the lowest quartile.
Fibroblast growth factor-23 (FGF-23) is associated with an elevated risk of death and of cardiovascular (CV) events in patients with chronic kidney disease (CKD), according to findings published in the Journal of the American Society of Nephrology.
Estimated glomerular filtration rate (eGFR) is linked just as tightly to chronic kidney disease (CKD) complications as the more invasive and cumbersome iothalamate GFR (iGFR) test in a recent study, results that challenges the conventional view that iGFR is the gold-standard measure of kidney function.
Saw palmetto fruit extracts are widely used to treat lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH), but a new study shows that these extracts are no better than placebo at easing symptoms, according to investigators.
An analysis of hospital admissions from 1991 to 2007 for 17,472 men who underwent prostate biopsy and 134,977 controls revealed a 30-day hospitalization rate of 6.9% within 30 days of biopsy—substantially higher than the 2.7% in the control population.
The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men with both erectile dysfunction (ED) and BPH.
Prostate cancer (PCa) is more likely to be diagnosed in men who have been hospitalized for clinical benign prostatic hyperplasia (BPH) or undergone surgery for the condition, according to a Danish study.
A recent analysis of data from 1,255 diabetic hemodialysis (HD) patients found that low levels of homoarginine are a strong risk factor for sudden cardiac death (SCD) and death due to heart failure in this population.
In a long-term randomized trial of 150 kidney transplant recipients with a median follow-up of eight years post-transplant, those undergoing immunosuppressive therapy with tacrolimus/mycophenolate mofetil (MMF) experienced significantly less frequent acute rejection (12%) than those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%).
Testing for the genetic anomaly TMPRSS2:ERG in conjunction with use prostate cancer antigen 3 (PCA3) is better at predicting the presence of prostate cancer (PCa) than either marker alone, according to a report in Science Translational Medicine.